Home > Research > Publications & Outputs > Clinical features of oral chemotherapy : result...
View graph of relations

Clinical features of oral chemotherapy : results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK.

Research output: Contribution to journalJournal article

Published

Standard

Clinical features of oral chemotherapy : results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK. / Brearley, Sarah G.; Craven, O.; Saunders, M.; Swindell, R.; Molassiotis, A.

In: European Journal of Cancer Care, Vol. 19, No. 4, 07.2010, p. 425-433.

Research output: Contribution to journalJournal article

Harvard

APA

Vancouver

Author

Brearley, Sarah G. ; Craven, O. ; Saunders, M. ; Swindell, R. ; Molassiotis, A. / Clinical features of oral chemotherapy : results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK. In: European Journal of Cancer Care. 2010 ; Vol. 19, No. 4. pp. 425-433.

Bibtex

@article{780d19874dd14fdbb1f7eb9722d03720,
title = "Clinical features of oral chemotherapy : results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK.",
abstract = "The aim was to describe the clinical sequelae of patients treated with capecitabine in terms of adverse events, treatment modifications and therapy cessation throughout the treatment trajectory. A total of 1232 toxicity assessments were undertaken on colorectal and breast cancer patients receiving palliative and adjuvant treatment prior to treatment and at days 7, 14 and 21 for six cycles of chemotherapy. Most common adverse events were diarrhoea, nausea, palmar-plantar erythrodysesthesia (PPE), fatigue and pain which were experienced by over 80{\%} of subjects. Grades 2 and 3 adverse events were common (n= 916 and n= 113) but their development into grade 4 was uncommon (n= 2). There was a downward trend in the percentage incidence of toxicity; however, PPE increased. Almost 60{\%} of subjects completed six cycles, or planned treatment. Some 40{\%} of subjects commenced treatment on a dose reduction (<1250 mg/m2), and this increased to 70{\%} at cycle 6. In total, 2.8–11.6{\%} of subjects experienced toxicity-related treatment deferrals. While adverse events are common with capecitabine the lack of grade 4 adverse events support the efficacy of current clinical management strategies. The deferral and dose reduction data indicate that cycles 1 and 2 are important and require careful management and clinical interventions in order to prevent high-grade adverse events.",
keywords = "capecitabine, colorectal cancer, breast cancer, toxicity, deferrals, dose",
author = "Brearley, {Sarah G.} and O. Craven and M. Saunders and R. Swindell and A. Molassiotis",
year = "2010",
month = "7",
doi = "10.1111/j.1365-2354.2009.01114.x",
language = "English",
volume = "19",
pages = "425--433",
journal = "European Journal of Cancer Care",
issn = "0961-5423",
publisher = "Wiley-Blackwell",
number = "4",

}

RIS

TY - JOUR

T1 - Clinical features of oral chemotherapy : results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK.

AU - Brearley, Sarah G.

AU - Craven, O.

AU - Saunders, M.

AU - Swindell, R.

AU - Molassiotis, A.

PY - 2010/7

Y1 - 2010/7

N2 - The aim was to describe the clinical sequelae of patients treated with capecitabine in terms of adverse events, treatment modifications and therapy cessation throughout the treatment trajectory. A total of 1232 toxicity assessments were undertaken on colorectal and breast cancer patients receiving palliative and adjuvant treatment prior to treatment and at days 7, 14 and 21 for six cycles of chemotherapy. Most common adverse events were diarrhoea, nausea, palmar-plantar erythrodysesthesia (PPE), fatigue and pain which were experienced by over 80% of subjects. Grades 2 and 3 adverse events were common (n= 916 and n= 113) but their development into grade 4 was uncommon (n= 2). There was a downward trend in the percentage incidence of toxicity; however, PPE increased. Almost 60% of subjects completed six cycles, or planned treatment. Some 40% of subjects commenced treatment on a dose reduction (<1250 mg/m2), and this increased to 70% at cycle 6. In total, 2.8–11.6% of subjects experienced toxicity-related treatment deferrals. While adverse events are common with capecitabine the lack of grade 4 adverse events support the efficacy of current clinical management strategies. The deferral and dose reduction data indicate that cycles 1 and 2 are important and require careful management and clinical interventions in order to prevent high-grade adverse events.

AB - The aim was to describe the clinical sequelae of patients treated with capecitabine in terms of adverse events, treatment modifications and therapy cessation throughout the treatment trajectory. A total of 1232 toxicity assessments were undertaken on colorectal and breast cancer patients receiving palliative and adjuvant treatment prior to treatment and at days 7, 14 and 21 for six cycles of chemotherapy. Most common adverse events were diarrhoea, nausea, palmar-plantar erythrodysesthesia (PPE), fatigue and pain which were experienced by over 80% of subjects. Grades 2 and 3 adverse events were common (n= 916 and n= 113) but their development into grade 4 was uncommon (n= 2). There was a downward trend in the percentage incidence of toxicity; however, PPE increased. Almost 60% of subjects completed six cycles, or planned treatment. Some 40% of subjects commenced treatment on a dose reduction (<1250 mg/m2), and this increased to 70% at cycle 6. In total, 2.8–11.6% of subjects experienced toxicity-related treatment deferrals. While adverse events are common with capecitabine the lack of grade 4 adverse events support the efficacy of current clinical management strategies. The deferral and dose reduction data indicate that cycles 1 and 2 are important and require careful management and clinical interventions in order to prevent high-grade adverse events.

KW - capecitabine

KW - colorectal cancer

KW - breast cancer

KW - toxicity

KW - deferrals

KW - dose

UR - http://www.scopus.com/inward/record.url?scp=77954764844&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2354.2009.01114.x

DO - 10.1111/j.1365-2354.2009.01114.x

M3 - Journal article

VL - 19

SP - 425

EP - 433

JO - European Journal of Cancer Care

JF - European Journal of Cancer Care

SN - 0961-5423

IS - 4

ER -